ZoomRx HCP Community

ZoomRx HCP Community ZoomRx HCP Community is a platform for US/UK based HCPs where they can learn about the latest developments in healthcare space and ZoomRx surveys

Ofatumumab isn’t just another MS therapy, it’s a shift in mechanism. Unlike oral immunomodulators like fingolimod or fu...
10/05/2025

Ofatumumab isn’t just another MS therapy, it’s a shift in mechanism. Unlike oral immunomodulators like fingolimod or fumarates, Ofatumumab precisely targets CD20+ B cells, eliminating their pro-inflammatory activity at the source.

This B-cell–depleting approach offers deeper, more sustained disease control, redefining how we manage relapsing MS.

💡 Key takeaway: Targeting B cells means targeting the root of inflammation, not just the symptoms.

🧬 Personalized care for skin cancer is here! A new genomic test - DecisionDx-SCC can predict the risk of recurrence and ...
09/28/2025

🧬 Personalized care for skin cancer is here!

A new genomic test - DecisionDx-SCC can predict the risk of recurrence and metastasis after a squamous cell carcinoma (SCC) diagnosis.

By analyzing 40 genes, the test places patients into low, higher, or highest-risk groups.

This helps doctors:
✔️ Decide if adjuvant radiation is needed ✔️ Plan how often follow-ups should happen
✔️ Catch aggressive cases earlier 🚨 📊

Studies show it improves accuracy beyond traditional risk factors giving both patients and doctors more clarity and confidence.

✨ FDA Breakthrough in Breast Cancer Care! ✨ The FDA has just approved Imlunestrant, the first oral SERD for adults with ...
09/28/2025

✨ FDA Breakthrough in Breast Cancer Care! ✨
The FDA has just approved Imlunestrant, the first oral SERD for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who progressed after prior endocrine therapy.

💊💙 Backed by the phase 3 EMBER-3 trial, Imlunestrant showed improved progression-free survival and higher response rates compared to standard options.

Plus, the Guardant360 CDx blood test is now FDA-approved to identify patients who can benefit.

🧬 A new step forward in making treatment more personalized, targeted & effective. 🌍✨

Can combining non-drug therapies with standard medicine improve GERD outcomes? A new systematic review & meta-analysis (...
09/21/2025

Can combining non-drug therapies with standard medicine improve GERD outcomes?

A new systematic review & meta-analysis (34 trials · ~3,000 patients · 2001–2024) shows that approaches like acupuncture, acupoint stimulation, breathing training, diet, and surgery—when combined with conventional Western medicine (CWM) may:
✅ Strengthen the reflux barrier (LES pressure)
✅ Reduce acid exposure (AET)
✅ Improve quality of life
✅ Lower side effects compared to some surgical options

✨ Integrative care could be the key to safer, more effective GERD management.

#/

lts from ESC 2025 highlight the promise of Pulsed Field Ablation (PFA) in atrial fibrillation. Compared to radiofrequenc...
09/14/2025

lts from ESC 2025 highlight the promise of Pulsed Field Ablation (PFA) in atrial fibrillation. Compared to radiofrequency ablation (RFA):

✅ Similar 1-year success in preventing AF recurrence
✅ Faster procedure times (almost 40 minutes shorter)
✅ Fewer complications & no pulmonary vein stenosis 👉

Surgical innovation and targeted therapies are transforming the ovarian cancer landscape. ✨ From expanding cytoreductive...
09/14/2025

Surgical innovation and targeted therapies are transforming the ovarian cancer landscape.

✨ From expanding cytoreductive expertise to the arrival of antibodies–drug conjugates like mirvetuximab soravtansine, the treatment paradigm is shifting toward greater precision and better outcomes.

📌 As we move forward, integrating advanced surgical strategies with novel therapeutics could redefine survival and quality of life for patients with ovarian cancer.

👁✨ A new specialized eye scan is revealing more than vision, it’s uncovering hidden nerve damage in women with epilepsy....
09/07/2025

👁✨ A new specialized eye scan is revealing more than vision, it’s uncovering hidden nerve damage in women with epilepsy.

🔍 Findings show:
• Shorter nerve fibers
• Lower nerve complexity
• Greater disorganization

This breakthrough could mean real-time monitoring, early diagnosis, and better care for neuro-endocrine conditions💡

Medicine is deeply rewarding but every specialty comes with its own joys and challenges when it comes to balance.From pr...
09/04/2025

Medicine is deeply rewarding but every specialty comes with its own joys and challenges when it comes to balance.

From procedures that offer instant answers to the flexibility of primary care, here’s what doctors told us about finding happiness in their work.

➡️ Swipe through to hear their voices.
❤️ Double-tap if you relate.
💬 Comment below: What helps you find balance in your specialty?

❤️ ❤️

"A targeted radiation boost = years of extra cancer control. 🚀 The FLAME trial shows that precision dosing in prostate c...
08/22/2025

"A targeted radiation boost = years of extra cancer control.

🚀 The FLAME trial shows that precision dosing in prostate cancer doesn’t just work—it changes outcomes.

Less recurrence. No added toxicity. More men spared the burden of cancer coming back.

💡 Would you consider focal boosting the new standard for high-risk prostate cancer?"


🧠 Could a “harmless” virus be playing a hidden role in Parkinson’s disease?A new study has found Human Pegivirus (HPgV),...
08/07/2025

🧠 Could a “harmless” virus be playing a hidden role in Parkinson’s disease?

A new study has found Human Pegivirus (HPgV), once considered harmless, in the brains and spinal fluid of Parkinson’s patients only, not in healthy individuals. What’s more intriguing?

🧬 The immune system’s response to the virus varied depending on genetic mutations like LRRK2, suggesting a complex dance between genes, viruses, and immunity.

🛡️ We might be entering a new era of Parkinson’s research.

👉 Swipe through to unpack the findings. 🔖 Save this post to revisit later.

🧬 Big News in Rare Disease Treatment!The EMA has recommended Aqneursa for Niemann-Pick Type C, a devastating neurodegene...
07/26/2025

🧬 Big News in Rare Disease Treatment!

The EMA has recommended Aqneursa for Niemann-Pick Type C, a devastating neurodegenerative disease affecting children and young adults.

Backed by strong trial data and showing real promise in improving brain function, this is a hopeful step forward.

🔬 Works with or without Miglustat
📈 Statistically proven benefits

🇪🇺 EMA thumbs-up = big win for NPC families

⚠️ Blenrep's Return Blocked by FDA PanelDespite showing promise in treating relapsed/refractory multiple myeloma, belant...
07/23/2025

⚠️ Blenrep's Return Blocked by FDA Panel

Despite showing promise in treating relapsed/refractory multiple myeloma, belantamab mafodotin's comeback was halted due to dosing missteps and significant ocular toxicity.

👁️ 90%+ patients reported vision-related side effects.
📉 Strong efficacy data couldn’t outweigh the risks.
👉 Should the FDA push for dose optimization before rejection?
Let us know your thoughts.

Join our panel of healthcare professionals today, your insights can help make a real-world impact! Link in bio☝️

Address

Boston
Massachusetts

Website

Alerts

Be the first to know and let us send you an email when ZoomRx HCP Community posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to ZoomRx HCP Community:

Shortcuts

Share

Category